Background: Valproic acid (VPA) has shown potent anti-inflammatory effect and attenuates acute lung injury. Aim: To determine whether the use of VPA is associated with a decreased risk of acute respiratory failure (ARF) in patients with subarachnoid hemorrhage (SAH). Design: The Taiwan National Health Insurance Research Database was used to analyse all patients newly diagnosed with SAH from 2000 to 2010. The VPA users were matched for age, gender and index date in 1:2 ratios with randomly selected non-VPA users as a comparison group. Methods: Multivariate Cox regression was used to identify the predictors of ARF and to compare the incidence rates of ARF among SAH patients using and not using VPA. Results: The study cohort included 16 228 newly diagnosed SAH patients, from which 521 VPA users and 1042 matched non-VPA-exposed individuals were selected. In the VPA-treated cohort and the non-VPA-treated cohort, 117 and 289 patients developed ARF, respectively. Any use of VPA was associated with a 16% decreased risk of ARF requiring mechanical ventilation in 30-day tracking of the SAH patients (adjusted hazard ratio [HR], 0.840, 95% confidence interval [CI], 0.676-0.945). Age, sepsis and pneumonia were identified as independent predictors of ARF in patients with SAH. After stratification, VPA users showed a lower risk of ARF among SAH patients complicated with pneumonia compared with non-users of VPA (adjusted HR, 0.816, 95% CI, 0.652-0.921). Conclusions: Any use of VPA was associated with a reduced risk of ARF in patients with SAH. VPA may be beneficial for decreasing the risk of pneumonia-induced ARF in patients with SAH.
Introduction
Subarachnoid hemorrhage (SAH) is a neurological emergency with an estimated mortality rate of 19-40%. [1] [2] [3] Although the initial hemorrhage and vasospasm are the major contributors to SAH-related mortality, non-neurological complications also result in mortality rate of 10-23%. 3, 4 The most common nonneurological complications after SAH are pulmonary complications, which include pneumonia, aspiration and pulmonary edema; these complications can cause poor outcomes and even death. 3, 5, 6 A population-based study conducted in South Carolina revealed that the most common medical complication after hospital admission of SAH patients is acute respiratory failure (ARF), which occurred in 43.5% of patients. 7 In addition, two multicenter studies also showed that ARF occurred more frequently in patients with acute brain injury, including SAH, compared with non-neurological patients in intensive care units (ICUs). 8, 9 Infection and inflammatory responses are important causes of ARF after acute cerebral insult. 10 Several cohort studies have demonstrated that up to 29-54% of patients with SAH develop systemic inflammatory response syndrome (SIRS), and more than 25% of SIRS cases are complicated with related acute lung injury (ALI). 4, [10] [11] [12] SAH promotes the release of proinflammatory cytokines, the production of reactive oxygen species and the expression of the neutrophil elastase, which together enhance pulmonary vascular permeability, potentially resulting in ALI and subsequent ARF. 6 Pneumonia is the most prevalent nosocomial infection occurring after SAH and is a major cause of ARF. 13 Another possible mechanism for ARF is the massive release of catecholamines induced by hypothalamic stress from SAH. This release can cause hydrostatic pressure injury to the pulmonary capillaries, resulting in neurogenic pulmonary edema. [14] [15] [16] Epileptic seizures occur in up to 25% of patients following an episode of SAH and increase the risk of re-bleeding and death. 17 The use of antiepileptic drugs for seizure prophylaxis in patients with SAH may be beneficial. 18 For example, valproic acid (VPA), which inhibits cytochrome P450 and has been widely used to treat epilepsy, migraines and manic disorder, 19 is also a class I histone deacetylase (HDAC) inhibitor that has shown potent antiinflammatory actions in animal models of hemorrhagic shock, trauma and septic shock through modulation of the mitogenactivated protein kinase cascade. 20 Recently, mouse experiments have demonstrated that VPA can attenuate lipopolysaccharide and ischemia/reperfusion-induced acute lung injury by enhancing the expression of the antioxidant enzyme hemooxygenase-1. 21, 22 Therefore, VPA therapy may be a novel approach to attenuate ALI and decrease the risk of ARF in SAH patients. However, no population-based evidence for the use of VPA and ARF in patients with preexisting SAH has been reported. To the best of our knowledge, this is the first human study to examine the effect of VPA on the risk of ARF in SAH patients. We used the Taiwan National Health Insurance Research Database (NHIRD) to identify SAH patients. The goal of our study was to investigate whether the use of VPA can decrease the risk of ARF in patients with SAH. We also identified the risk factors and clinical conditions that contribute to ARF in patients with SAH.
Materials and methods

Data source
The NHIRD consists of claims records from Taiwan's Universal National Health Insurance (NHI) program dating from 1995 and covering more than 99% of the population. To protect patient privacy, all personal identification information is encrypted prior to the data being released for research purposes. In this study, we used a NHIRD subset that contained healthcare data, including files from the Longitudinal Health Insurance Database (LHID). The LHID has been widely used to investigate the association of drug safety with adverse respiratory events. 
Study cohort
Patients newly diagnosed with SAH (ICD-9-CM code 430) between 1 January 2000 and 31 December 2010 were identified in the LHID (Figure 1) . We excluded any patients with a history of SAH, ARF (ICD-9-CM code 518.4, 518.51, 518.53, 518.81, 518.82, 518.84, 786.09), or mechanical ventilation (ICD-9-CM OP93.90, OP96.70-OP96.72) prior to follow-up; those who were younger than 18 years old; and those who had incomplete information with regard to gender. The date of initial SAH diagnosis served as the index date. For the VPA-treated cohort, we randomly chose SAH patients treated with VPA from the LHID and frequency-matched those with non-VPA-treated SAH patients using a 1:2 ratio based on gender, age and index date. VPA treatment during SAH and post-SAH within 30 days after the index date was included in our study.
Outcomes and comorbidities
Preexisting comorbidities, such as epilepsy (ICD-9-CM 345), manic disorder (ICD-9-CM 296), migraine (ICD-9-CM 346), coronary atherosclerosis (ICD-9-CM 414.0), heart failure (ICD-9-CM 428.0-428.9), hypertension (ICD-9-CM 401), diabetes (ICD-9-CM 250), malignant neoplasm (ICD-9-CM 196, 199), chronic obstructive pulmonary disease (COPD) (ICD-9-CM 491-492, 496), and chronic kidney disease (CKD) (ICD-9-CM 585), were used for analysis. Furthermore, the following codes were used to select patients for the following hospital complications: ARF, defined as ARF (ICD-9-CM code 518. 4 
Statistical analysis
We compared the distributions of categorical characteristics and baseline comorbidities between the VPA-treated and non-VPA-treated groups using the v 2 test and Fisher's exact test. Differences in continuous variables between the cohorts were assessed using Student's t-test. The cumulative incidence of ARF between the VPA-treated and non-VPA-treated cohorts was assessed using the Kaplan-Meier method, and the log-rank test was applied to compare the two cohorts. Multivariate Cox proportional hazards regression models were used to calculate the incidence densities (per 10 5 personyears) of ARF in the VPA-treated and non-VPA-treated cohorts, which were expressed as the hazard ratio (HR) with 95% confidence interval (CI). The multivariate models adjusted for gender, age, epilepsy, manic disorder, migraine, coronary atherosclerosis, heart failure, hypertension, thrombocytopenia, malignant neoplasm, diabetes, COPD, CKD, sepsis, cardiovascular dysfunction, hematological dysfunction, hepatic dysfunction, renal dysfunction, neurological dysfunction and pneumonia. The selected variables were clinically relevant to the development of ARF based on previous studies. 24, 26, 27 Both cohorts were also stratified by epilepsy, manic disorder, migraine, coronary atherosclerosis, heart failure, hypertension, malignant neoplasm, diabetes, COPD, CKD, sepsis, cardiovascular dysfunction, hematological dysfunction, hepatic dysfunction, renal dysfunction, neurological dysfunction and pneumonia and then analysed using the Cox models. All analyses were conducted using SAS, Version 9.3 (SAS Institute Inc., Cary, NC), with the significance level set at 0.05 in two-tailed tests.
Results
Patient demographics
We identified 26 700 SAH patients from the LHID and 16 228 of these individuals were analysed after applying the exclusion criteria. All study patients were adults and had been newly diagnosed with SAH. The VPA-treated group consisted of 521 individuals, and the comparison group consisted of 1042 individuals matched for gender, age and index date ( Figure 1 ). The age distributions of the VPA-treated and non-VPA-treated cohorts were 56.27 6 15.44 and 58.09 6 15.77, respectively. The most common disease that required VPA use before SAH in our study was epilepsy. No significant differences were found in comorbidities, including epilepsy, manic disorder, migraine, coronary atherosclerosis, congestive heart failure, hypertension, malignant neoplasm, diabetes, COPD and CKD or in age and gender between the VPA-treated and non-VPA-treated groups ( Table 1 ). The Kaplan-Meier calculation of the cumulative incidence of ARF was significantly lower in the VPA-treated cohort than in the non-VPA-treated cohort (log rank test, P < 0.05) (Figure 2 ). Table 2 reveals the incidence of adverse events during the 30-day follow-up period. In total, 117 and 289 patients with ARF were divided into VPA-treated and non-VPA-treated groups, respectively. The incidence of ARF in the VPA-treated group was significantly lower than in the non-VPA-treated group (22.46% vs. 27.74%, P ¼ 0.014). In addition, the VPA users had a significantly lower incidence of pneumonia (84.84% vs. 92.23%, P < 0.001) compared with the non-VPA users at the end of the follow-up. The median timeframe of ARF after SAH was 15.9 days in the VPA-treated group and 13.7 days in the non-VPA-treated group. The incidence of epilepsy and neurological dysfunction was lower in the VPA-treated group than the non-VPA-treated group, but the difference was not significant.
The multivariate Cox regression analysis revealed that any use of VPA, age, sepsis and pneumonia were independent risk factors for ARF, whereas neurological or cardiovascular dysfunction was not a risk factor (Table 3) . Any use of VPA was associated with a 16% decreased risk of ARF (adjusted HR, 0.840, 95% CI, 0.676-0.945). The cumulative dose of VPA within 30 days after the index date was also associated with a trend toward a decreased risk of ARF (adjusted HR, 0.869, 95% CI, 0.642-1.003), but the decrease was not significant (not shown in the table). The median cumulative dose of VPA within 30 days was 29.36 6 33.41 g. The receiver operator characteristic (ROC) curve revealed that the optimal cut-off value for protection from ARF within 30 days after SAH was 28.5 g. The area under the ROC curve was 0.738, with a sensitivity of 62.1% and specificity of 70.4% (P < 0.001) (Figure 3 ). The risk of ARF was increased by year of age and in the presence of the adverse complications sepsis and pneumonia. After stratification, the incidence rates of pneumonia in the SAH patients with ARF in the VPA-treated and non-VPA-treated groups were 13 568 and 19 911 per 100 000 person-years, respectively, yielding an adjusted HR of 0.816 (95% CI 0.652-0.921) ( Table 4) . The above results indicate that VPA exerts a protective effect on ARF in SAH patients potentially by attenuating the adverse effects of pneumonia.
Discussion
Our study included 406 incident cases of ARF identified among 1563 patients with SAH. There was an overall 16.0% decrease in the risk of ARF with any use of VPA, independent of neurological and cardiovascular dysfunction. Older age, sepsis and pneumonia were independently associated with the development of ARF in patients with SAH. After stratification, VPA was found to attenuate the risk of ARF in SAH patients complicated with pneumonia. The results of this study indicate that VPA could decrease the incidence of ARF in SAH patients, which may result from the anti-inflammatory effect of VPA in pneumoniainduced ALI.
HDACs play critical roles in regulating protein acetylation in histones and modulating cellular activity. HDAC inhibitors Figure 2 . Cumulative incidence of acute respiratory failure requiring mechanical ventilation among patients using valproic acid and the comparison group subjects (dashed line) (log-rank P ¼ 0.017). promote the acetylation of nuclear histone proteins and exert protective effects in animal models of inflammatory disease, including hepatitis and systemic lupus erythematosus. 28 VPA is the only HDAC inhibitor used in humans that has also shown strong anti-inflammatory effects in different animal models. 21, 22, 29, 30 In one experimental study, VPA attenuated lung ischemia/reperfusion injury in rats by decreasing the production of inflammatory cytokines and reactive oxygen species, reducing acute lung edema and blocking nuclear factor-j B signaling. 22 VPA also attenuated the expression of lung cytokineinduced neutrophil chemoattractant-1 and prevented hemorrhage-induced ALI in rats. 31 Based on the above findings, it is reasonable to assume that the decreased risk of ARF in patients with SAH that results from VPA treatment may be due to the anti-inflammatory effects of VPA, which could help ameliorate pneumonia-and sepsis-related ALI. ALI is a leading cause of ARF in the ICU. 32 A large multicenter study demonstrated that patients with severe head injury frequently develop pulmonary infections (41% of patients) and that this is a significant independent predictor of an unfavorable outcome. 9 Another prospective study revealed that patients exhibited pronounced immunodepression after SAH, as shown by the significantly decreased CD4þ T cell, CD8þ T cell and natural killer cell populations, and that this depression was associated with a very high incidence of pneumonia (67%). 33 Consistent with a prior study, we found that SAH patients with pneumonia or sepsis were more likely to develop ARF and receive mechanical ventilation compared to patients without pneumonia or sepsis. 27 A high incidence rate of pneumonia (89.76% in all SAH patients at the end of follow-up) was observed in our study, and the use of VPA reduced this incidence, indicating that VPA may have a protective effect against pneumonia in SAH patients. No prior studies have investigated the association between VPA and the development of pneumonia in patients with SAH. The mechanism through which VPA decreased the incidence of pneumonia requires further examination, including in vitro studies to examine the possible antiinfective effects of VPA. Sepsis can cause the overproduction of pro-inflammatory cytokines, increase lung permeability, promote pulmonary edema and enhance neutrophil infiltration into the lung, which is a frequent cause of ALI and subsequent ARF. 21, 32 Patients with acute brain insults develop sepsis and ARF more frequently than other patients in the ICU. 8, 9 Several cohort studies have demonstrated that severe sepsis is independently associated with the development of ALI and poor outcomes in SAH patients. 12 In a mouse model of lipopolysaccharide-induced ALI, VPA improved sepsis-related lung injury by inhibiting NFkB activation and neutrophil infiltration in the lung. 21 Our study also showed that sepsis is an independent risk factor for ARF in SAH patients, with an overall 3.3% incidence rate for sepsis in this group. However, VPA was not found to reduce the incidence of sepsis-related ARF in multivariate Cox regression analysis. Furthermore, we found that older age was associated with an increased risk of ARF, which may result from the higher incidence of pneumonia after SAH that is present in patients of older age. 34 In addition to pulmonary complications, SAH also causes neurological adverse events associated with ARF, such as vasospasm, cerebral edema, delayed cerebral ischemia or rebleeding, which can result in impairments in arousal and airway protection that increase the risk of aspiration pneumonia in patients. A previous study showed that VPA can attenuate SAH-related delayed vasospasm by decreasing the expression of adhesion molecules and reducing neuro-inflammation in rats. 30 VPA also mediates heat shock protein 70/matrix metallopeptidase 9 to prevent blood-brain barrier disruption and cerebral edema. 35 VPA may reduce neurological adverse events and decrease the risk of aspiration and subsequent ARF. Post-SAH epilepsy is another issue that can result in reduced consciousness and postictal aspiration risk. One potential reason for why VPA use decreased the incidence of pneumonia could be that VPA decreased the incidence of epilepsy and avoided subsequent aspiration events. Nonetheless, the multivariate Cox regression model indicated that neurological dysfunction and epilepsy were not independent predictors of ARF in our study. Additional prospective studies are needed to clarify the association between VPA and neurological adverse events in patients with SAH.
The main strength of the study was the lack of selection bias related to age, gender or race, owing to the fact that it was a nationwide cohort longitudinal analysis. Several limitations of this study should be considered. First, it is difficult to ascertain the compliance with VPA therapy in a nationwide study. However, this problem may be relatively minor because our study period was 30 days, and drug compliance is generally higher in the ICU or in other hospital units compared to at home. Second, there is a lack of clinical details, such as Glasgow Coma Scale, SAH severity, Hunt-Hess score, Fisher score, postbleeding vasospasm, causative pathogens, laboratory data and the use of sedatives, in the claims database, which limits understanding of the relationships between these variables and ARF. Third, the NHIRD did not provide information on health-related factors such as smoking and body mass index, which may increase the risk of ARF. Finally, we did not know whether the included patients had been previously exposed to VPA. However, we did adjust for populations that might have received VPA therapy, such as individuals with epilepsy, manic disorder or migraine. In the future, a large prospective study should be performed to confirm the possible protective role of VPA on ARF in patients with SAH. people. *P < 0.05; **P < 0.01; ***P < 0.001. 
Conclusion
This is the first human study to estimate the risk of ARF associated with VPA therapy among a nationwide cohort of individuals with SAH. We found that VPA may decrease the risk of ARF in SAH patients, especially those complicated with pneumonia.
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